Ulipristal Acetate - A New Treatment Modality in Fibroid Uterus: Efficacy and Safety

Main Article Content

Dr. Sanchita Karmakar

Abstract

Objective: To study the efficacy and safety of ulipristal acetate in the medical management of fibroid uterus.



Materials and methods: A total of 36 cases of fibroid uterus aged between 25 to 50 years, who had completed family were assigned to receive ulipristal acetate 5 mg once daily for three months. Patients were followed up at end of three month of therapy, and then one month after treatment was stopped. The parameters evaluated were menstrual blood loss (MBL), haemoglobin level, volume of the uterus and fibroid, pain by numerical rating scale and the endometrial thickness. These parameters were measured at start of therapy (baseline), after three months of treatment and then one month after treatment was stopped. The side effects and patient acceptability of drug ulipristal acetate were assessed.



Results: Treatment with ulipristal acetate results in significant reduction of MBL, haemoglobin level, volume of the uterus and fibroid, pain. There was no statistically significant change seen in endometrial thickness (ET) with use of ulipristal acetate. Adverse effects reported were amenorrhoea, hot flushes, hypomenorrhoea and spotting. One case of mild liver injury was reported.



Conclusion: Ulipristal acetate is an effective therapeutic option for the medical management of fibroid uterus in properly selected cases. During the treatment period liver function test should be monitored.



Keywords: Menstrual blood loss; Haemoglobin; Endometrial thickness

Published May 22, 2020

Article Details